The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...

Meanwhile, the UK launch of Freestyle Libre 3 comes as rival real-time CGM player Dexcom received a European CE mark for its G7 device for people with diabetes aged two years and older.

Abbott has received an innovation award for Lingo, its first consumer biowearable over-the-counter device designed to support ...

Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device to empower people in ...